BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
3期
已完成
NCT03762018
| 适应症 | Pleural Mesothelioma Malignant Advanced |
|---|
| 分期 | 3期 |
|---|
| 申办方 | ETOP IBCSG Partners Foundation |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 400 人 |
|---|
| 干预（药物） | Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab |
|---|
| 开始日期 | 2019年4月30日 |
|---|
| 完成日期 | 2023年9月1日 |
|---|
| 结果公布日 | 2026年5月14日 |
|---|
摘要
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.
Overall Survival (OS)
From randomization until death from any cause, up to 52 months. · months
| Atezolizumab Plus Bevacizumab Plus Chemotherapy | 20.5 months |
|---|
| Bevacizumab Plus Chemotherapy | 18.1 months |
|---|
| p-value | 0.14 |
|---|
| Hazard Ratio (HR) | 0.84 (95% CI 0.66–1.06) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。